CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November...

CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday,
November 6, 2008

PALO ALTO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.
(Nasdaq: CVTX) today announced that it will release third quarter financial
results for 2008 after the market closes on Thursday, November 6, 2008.
Company management will webcast a conference call at 5:00 p.m. EST, 2:00 p.m.
PST, on the company's website.

To access the live webcast, please log on to the Company's website at
www.cvt.com and go to the Investor Information section. Alternatively,
domestic callers may participate in the conference call by dialing (866)
524-6241, and international callers may participate in the conference call by
dialing (706) 679-3061. Webcast and telephone replays of the conference call
will be available approximately two hours after the completion of the call
through Thursday, November 13, 2008. Domestic callers can access the replay by
dialing (800) 642-1687, and international callers can access the replay by
dialing (706) 645-9291; the PIN access number is 68392680.

About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company primarily focused on applying molecular cardiology
to the discovery, development and commercialization of novel, small molecule
drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is
the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R)
(ranolazine extended-release tablets), indicated for the treatment of chronic
angina in patients who have not achieved an adequate response with other
antianginal drugs, and Lexiscan(R) (regadenoson) injection for use as a
pharmacologic stress agent in radionuclide myocardial perfusion imaging in
patients unable to undergo adequate exercise stress. Ranexa(R) (ranolazine
prolonged-release tablets) is approved for use in the European Union as add-on
therapy for the symptomatic treatment of patients with stable angina pectoris
who are inadequately controlled or intolerant to first-line antianginal
therapies. CV Therapeutics also has other clinical and preclinical drug
development candidates and programs.

SOURCE CV Therapeutics, Inc.

John Bluth, Executive Director, Corporate Communications & Investor Relations
of CV Therapeutics, Inc., +1-650-384-8850